Browsing Tag
ReSPECT-LM
2 posts
What REYOBIQ’s Phase 1 data means for the future of CNS-directed radiopharmaceutical platforms
What does REYOBIQ’s Phase 1 data reveal about the future of CNS-targeted radiopharmaceuticals? Explore the broader neuro-oncology implications.
Investors eye Plus Therapeutics after promising ReSPECT-LM results and FDA fast-track push for REYOBIQ in brain metastases
See how Plus Therapeutics’ REYOBIQ delivered >75 percent benefit and no toxicity in its ReSPECT-LM trial—discover what this means for CNS cancer treatment and investors.